Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In

Fluorouracil

Brand and Other Names: Adrucil
Mechanism of Action:

Fluorouracil is a nucleoside metabolic inhibitor that interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extentinhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Fluorouracil is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′triphosphate (FUTP) and 5-fluoro-2′-deoxyuridine-5′- triphosphate (FdUTP). These metabolites have several effects including the inhibition of thymidylate synthase by FdUMP, incorporation of FUTP into RNA and incorporation of FdUTP into DNA.

Indications:

Fluorouracil is a nucleoside metabolic inhibitor indicated for the treatment of patients with:
• Adenocarcinoma of the Colon and Rectum 
• Adenocarcinoma of the Breast
• Gastric Adenocarcinoma
• Pancreatic Adenocarcinoma

Route: Intravenous
Dose:

•Fluorouracil is recommended for administration either as an intravenous bolus or as an intravenous infusion.
•See Full Prescribing Information for dose individualization and dose modifications due to adverse reactions.
•See Full Prescribing Information for recommended doses of fluorouracil for adenocarcinoma of the colon and rectum and for recommended doses of fluorouracil as a component of a chemotherapy regimen for adenocarcinoma of the breast, gastric adenocarcinoma, pancreatic adenocarcinoma
•Pharmacy Bulk Package: Prepare doses for more than one patient in a Pharmacy Admixture Service under appropriate conditions for cytotoxic drugs. Do not inject the entire contents of the vial directly into patients. Use within 4 hours of puncture.

Adverse Reactions:
Contraindication:
None.
Warnings and Precautions:
Increased Risk of Serious or Fatal Adverse Reactions in Patients with Low or Absent Dipyrimidine Dehydrogenase Activity: Withhold or permanently discontinue fluorouracil in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of dipyrimidine dehydrogenase (DPD) activity. No fluorouracil dose has been proven safe in patients with absent DPD activity. See package insert for complete information.
See package insert for full prescribing information.